Xu-Feng Jiang
Overview
Explore the profile of Xu-Feng Jiang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
118
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang N, Huang X, Jiang X, Wang L, Cheng S, Xu P, et al.
Hematol Oncol
. 2024 Dec;
43(1):e70012.
PMID: 39716437
Newly diagnosed follicular lymphoma (FL) patients usually received first-line rituximab-based immunochemotherapy (R-chemo). Recently, rituximab plus lenalidomide (R2) emerged as an alternative chemo-free immunotherapy. We performed a comparative analysis of positron...
2.
Sheng L, Shen R, Yan Z, Wang C, Zheng X, Zhang Y, et al.
Biomark Res
. 2024 Sep;
12(1):104.
PMID: 39272132
Chimeric antigen receptor T (CAR-T) cell therapy has greatly improved the prognosis of relapsed and refractory patients with large B-cell lymphoma (LBCL). Early identification and intervention of patients who may...
3.
Wang W, Jiang X, Zhang C, Zhan X, Cheng J, Tao L, et al.
J Hazard Mater
. 2024 Aug;
477:135376.
PMID: 39111175
Avermectin is a highly effective insecticide that has been widely used in agriculture since the 1990s. In recent years, the safety of avermectin for non-target organisms has received much attention....
4.
Wang W, Li S, Liu B, Tang N, Zhang C, Jiang X, et al.
Environ Res
. 2024 May;
257:119267.
PMID: 38815718
Natural pyrethrins are widely used in agriculture because of their good insecticidal activity. Meanwhile, natural pyrethrins play an important role in the safety evaluation of pyrethroids as precursors for structural...
5.
Xiong J, Dai Y, Wang W, Zhang H, Wang C, Yin T, et al.
Sci Bull (Beijing)
. 2023 Oct;
68(21):2607-2619.
PMID: 37798178
Epstein-Barr virus (EBV) is the oncogenic driver of multiple cancers. However, the underlying mechanism of virus-cancer immunological interaction during disease pathogenesis remains largely elusive. Here we reported the first comprehensive...
6.
Zhang M, Tian S, Fu D, Wang L, Cheng S, Yi H, et al.
Cancer Cell
. 2023 Sep;
41(10):1705-1716.e5.
PMID: 37774697
We report the results of GUIDANCE-01 (NCT04025593), a randomized, phase II trial of R-CHOP alone or combined with targeted agents (R-CHOP-X) guided by genetic subtyping of newly diagnosed, intermediate-risk, or...
7.
Shi Q, He Y, Yi H, Mu R, Jiang X, Fu D, et al.
Cancer Commun (Lond)
. 2023 Jul;
43(8):896-908.
PMID: 37403255
Background: The current standard of care for non-bulky diffuse large B-cell lymphoma (DLBCL) patients with an International Prognostic Index (IPI) of 0 is four cycles of rituximab plus cyclophosphamide, doxorubicin,...
8.
Zhang M, Fang Y, Xu P, Dong L, Shen R, Huang Y, et al.
Clin Transl Med
. 2021 Dec;
11(12):e584.
PMID: 34923760
No abstract available.
9.
Xie W, Liu M, Jiang X, Gao X, Li B, Wang L, et al.
Acta Oncol
. 2021 Mar;
60(6):735-743.
PMID: 33720799
Objectives: The positron emission tomography (PET) could predict the prognosis of DLBCL patients, but the exact procedure on interim PET (iPET) to determine chemoresistant patients remains elusive. Methods: We retrospectively...
10.
Zhang M, Fang Y, Wang L, Cheng S, Fu D, He Y, et al.
Clin Epigenetics
. 2020 Oct;
12(1):160.
PMID: 33097085
Background: Elderly patients with diffuse large B-cell lymphoma (DLBCL) present with poor clinical outcome and intolerance to intensive chemotherapy. Histone deacetylase inhibitors (HDACIs) show anti-lymphoma activities and can be applied...